Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 18, Art. 37 (pp. 551-560)    |    2017       

»

Thrombin generation in patients with hereditary thrombophilia, receiving anticoagulant therapy

FGBU Russian Research Institute of Hematology and Transfusiology, FMBA of Russia

Brief summary

Inherited thrombophilia is associated with a high risk of developing venous thromboembolism (VTE). Anticoagulant therapy is used for the treatment and prevention of VTE. Currently, new oral anticoagulants (NOAC), were appeared which, along with warfarin are used in clinical practice. Rivaroxaban - direct inhibitor of factor Xa is one of such drugs. The paper presents the results of the thrombin generation test (TGT) for carriers of mutations in genes of factors II (G20210A) and V (G1691A), receiving anticoagulant therapy with warfarin or rivaroxaban. Treatment with warfarin or rivaroxaban was accompanied by a decrease in the velocity and maximum concentration of thrombin. The efficiency of the protein C system was disrupted in patients receiving warfarin. Therapy with rivaroxaban contributed to a marked increase in the anticoagulant action of protein C system. The peculiarities of the mentioned drugs enhance the ability of clinicians to the individual approach to the treatment and prevention of VTE depending on clinical situation.


Key words

hereditary thrombophilia, thrombin generation test, venous thromboembolism, warfarin, rivaroxaban.

Reference list

1. Geneticheskie faktori riska razvitiya venoznih trombozov v rannem vozraste / A.M. Sheidina, O.V. Sirotkina i dr. // Voprosi sovremennoi pediatrii. - 2005. - T. 4. - N2. - S. 42-46.


2. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European prospective cohort on trombophilia / Vossen C.Y., Conard J., Fontcuberta J. et al. // Journal of Thrombosis and Haemostasis. - 2005. - N 3. - P. 459-64.


3. Bokeriya O.L. Otkajemsya li mi ot varfarina? / O.L. Bokeriya, T.I. Kopaliani // Annali aritmologii. - 2016. - T. 13. - N2. - S. 87-95.


4. Galstyan G.M. Naryshenie gemostaza, obyslovlennie deficitom vitamin K-zavisimih faktorov svertivaniya krovi - patogenez, sposobi korrekcii i rekomendacii po lecheniu / G.M. Galstyan // Gematologiya i transfyziologiya. - 2012. - T. 57. - N2. - S. 7-21.


5. Paikin J.S. Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCET AF trial / J.S. Paikin, J.J. Manolakos, J.W. Eikeldoom // Expert Review of Cardiovascular Therapy. - 2012. - 10(8) - P. 965-972.


6. Nikonov V.V. Mehanizm deistviya antikoagylyantov i perspektivi klinicheskogo primeneniya rivaroksabana - pervogo effektivnogo ingibitora faktora Ha s vozmojnostu enteralnogo vvedeniya / V.V. Nikonov, S.V. Kyrsov // Medicina neotlojnih sostoyanii. - 2011. - N10(34) - S. 52-57.


7. Use of calibrated automated thrombography thrombomodulin to recognize the prothrombotic phenotype / Dargaud Y., Trzeciak M., Borget J. et al. // Thrombosis and Haemostasis. - 2006. - N 96. - P. 562-567.


8. Calibrated automated thrombin generation measurement in clotting plasma. / Hemker H.C., Giesen P., Dieri R. Al et al // Pathophysiology of Haemostasis and Thrombosis. - 2003. - N33 - P. 4-15.


9. Znachenie testa generacii trombina v klinicheskoi praktike / U.A. Namestnikov, O.G. Golovina, L.P. Papayan // Tromboz, gemostaz i reologiya. - 2011 - 4(48) - S. 47-49.


10. MacCallum, P. Diagnosis and management of heritable thrombophilias / P. MacCallum, L. Bowles, D. Keeling // British Medical Journal. - 2014. - N17 - R. 349 - 358.


11. Izmenenie antikoagylyantnogo deistviya rivaroksabana na protyajenii sytok / I.V. Gelcer, O.A. Smirnova, O.U. Matvienko, O.G. Golovina, L.P. Papayan // Vestnik hiryrgii im. I.I.Grekova. - 2015. - T. 174. - N4. - S. 77-79.


12. Osobennosti deistviya peroralnih antikoagylyantov / I.V. Gelcer, O.A. Smirnova, O.U Matvienko i dr. // Serdce: jyrnal dlya praktikyushih vrachei. - 2015. - T. 14. -N3. - S. 154-157.